452 related articles for article (PubMed ID: 27790145)
1. Systemic Immune-Inflammation Index Predicts the Clinical Outcome in Patients with mCRPC Treated with Abiraterone.
Lolli C; Caffo O; Scarpi E; Aieta M; Conteduca V; Maines F; Bianchi E; Massari F; Veccia A; Chiuri VE; Facchini G; De Giorgi U
Front Pharmacol; 2016; 7():376. PubMed ID: 27790145
[No Abstract] [Full Text] [Related]
2. Systemic immune-inflammation index, serum albumin, and fibrinogen impact prognosis in castration-resistant prostate cancer patients treated with first-line docetaxel.
Man YN; Chen YF
Int Urol Nephrol; 2019 Dec; 51(12):2189-2199. PubMed ID: 31456101
[TBL] [Abstract][Full Text] [Related]
3. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
[TBL] [Abstract][Full Text] [Related]
4. Platelet-lymphocyte and neutrophil-lymphocyte ratios are prognostic but not predictive of response to abiraterone acetate in metastatic castration-resistant prostate cancer.
Lozano Martínez AJ; Moreno Cano R; Escobar Páramo S; Salguero Aguilar R; Gonzalez Billalabeitia E; García Fernández R; De La Fuente Muñoz I; Romero Borque A; Porras Martínez M; Lopez Soler F; Cardenas Cánovas E; Ortega Martín I
Clin Transl Oncol; 2017 Dec; 19(12):1531-1536. PubMed ID: 28718070
[TBL] [Abstract][Full Text] [Related]
5. Revealing the prognostic landscape of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with abiraterone or enzalutamide: a meta-analysis.
Guan Y; Xiong H; Feng Y; Liao G; Tong T; Pang J
Prostate Cancer Prostatic Dis; 2020 Jun; 23(2):220-231. PubMed ID: 32034294
[TBL] [Abstract][Full Text] [Related]
6. Systemic immune-inflammation index predicts the combined clinical outcome after sequential therapy with abiraterone and docetaxel for metastatic castration-resistant prostate cancer patients.
Fan L; Wang R; Chi C; Cai W; Zhang Y; Qian H; Shao X; Wang Y; Xu F; Pan J; Zhu Y; Shangguan X; Zhou L; Dong B; Xue W
Prostate; 2018 Mar; 78(4):250-256. PubMed ID: 29285775
[TBL] [Abstract][Full Text] [Related]
7. Prognostic role of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, systemic immune-inflammation index, and pan-immune-inflammation value in metastatic castration-resistant prostate cancer patients who underwent 177Lu-PSMA-617.
Şahin E; Kefeli U; Zorlu Ş; Seyyar M; Ozkorkmaz Akdag M; Can Sanci P; Karakayali A; Ucuncu Kefeli A; Bakkal Temi Y; Cabuk D; Uygun K
Medicine (Baltimore); 2023 Nov; 102(47):e35843. PubMed ID: 38013293
[TBL] [Abstract][Full Text] [Related]
8. The prognostic role of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and systemic immune-inflammation index on short- and long-term outcome following surgery for spinal metastases.
Ryvlin J; Kim SW; Hamad MK; Fourman MS; Eleswarapu A; Murthy SG; Gelfand Y; De la Garza Ramos R; Yassari R
J Neurosurg Spine; 2024 Apr; 40(4):475-484. PubMed ID: 38157531
[TBL] [Abstract][Full Text] [Related]
9. Systemic immune-inflammation index predicting chemoradiation resistance and poor outcome in patients with stage III non-small cell lung cancer.
Tong YS; Tan J; Zhou XL; Song YQ; Song YJ
J Transl Med; 2017 Oct; 15(1):221. PubMed ID: 29089030
[TBL] [Abstract][Full Text] [Related]
10. High systemic immune-inflammation index predicts poor prognosis in advanced lung adenocarcinoma patients treated with EGFR-TKIs.
Deng C; Zhang N; Wang Y; Jiang S; Lu M; Huang Y; Ma J; Hu C; Hou T
Medicine (Baltimore); 2019 Aug; 98(33):e16875. PubMed ID: 31415428
[TBL] [Abstract][Full Text] [Related]
11. Prognostic role of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with metastatic castration resistant prostate cancer treated with abiraterone or enzalutamide.
Pisano C; Tucci M; DI Stefano RF; Turco F; Samuelly A; Bungaro M; Vignani F; Tarenghi F; Scagliotti GV; DI Maio M; Buttigliero C
Minerva Urol Nephrol; 2021 Dec; 73(6):803-814. PubMed ID: 33781017
[TBL] [Abstract][Full Text] [Related]
12. The Relationship Between Preoperative Systemic Immune Inflammation Index and Prognostic Nutritional Index and the Prognosis of Patients With Alveolar Hydatid Disease.
Ren B; Chen X; Lei P; Hou L; Wang H; Zhou Y; Ren L; Fan H; Wang Z; Yuan J
Front Immunol; 2021; 12():691364. PubMed ID: 34248983
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of preoperative hematological markers in patients with glioblastoma multiforme and construction of random survival forest model.
Duan X; Yang B; Zhao C; Tie B; Cao L; Gao Y
BMC Cancer; 2023 May; 23(1):432. PubMed ID: 37173662
[TBL] [Abstract][Full Text] [Related]
14. The Predictive Value of Systemic Inflammatory Factors in Advanced, Metastatic Esophageal Squamous Cell Carcinoma Patients Treated with Camrelizumab.
Liu J; Gao D; Li J; Hu G; Liu J; Liu D
Onco Targets Ther; 2022; 15():1161-1170. PubMed ID: 36238132
[TBL] [Abstract][Full Text] [Related]
15. The Value of the Systemic Immune-Inflammation Index in Predicting Survival Outcomes in Patients with Brain Metastases of Non-Small-Cell Lung Cancer Treated with Stereotactic Radiotherapy.
Zhang Y; Chen Z; Jin F; Guo D; Chen Q; Liu Z; Ji S; Gao G
Mediators Inflamm; 2021; 2021():2910892. PubMed ID: 34744510
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of pre-treatment systemic immune-inflammation index in patients with endometrial cancer.
Matsubara S; Mabuchi S; Takeda Y; Kawahara N; Kobayashi H
PLoS One; 2021; 16(5):e0248871. PubMed ID: 33989285
[TBL] [Abstract][Full Text] [Related]
17. The prognostic value of inflammation markers in postoperative gliomas with or without adjuvant treatments.
Luo Y; Deng R; Zhong Q; Luo D; Li X; Chen X; Tao S; Feng Z; Jiayi L; Huang Y; Li J; Liu W
Medicine (Baltimore); 2021 Jun; 100(25):e26437. PubMed ID: 34160435
[TBL] [Abstract][Full Text] [Related]
18. High Systemic Immune-Inflammation Index Predicts Poor Survival in Patients with Human Epidermal Growth Factor Receptor-2 Positive Breast Cancer Receiving Adjuvant Trastuzumab.
Jiang L; Fang J; Ding J
Cancer Manag Res; 2020; 12():475-484. PubMed ID: 32021460
[TBL] [Abstract][Full Text] [Related]
19. The predictive value of a preoperative systemic immune-inflammation index and prognostic nutritional index in patients with esophageal squamous cell carcinoma.
Zhang H; Shang X; Ren P; Gong L; Ahmed A; Ma Z; Ma R; Wu X; Xiao X; Jiang H; Tang P; Yu Z
J Cell Physiol; 2019 Feb; 234(2):1794-1802. PubMed ID: 30070689
[TBL] [Abstract][Full Text] [Related]
20. The prognostic power of inflammatory indices and clinical factors in metastatic castration-resistant prostate cancer patients treated with radium-223 (BIO-Ra study).
Bauckneht M; Rebuzzi SE; Signori A; Frantellizzi V; Murianni V; Lodi Rizzini E; Mascia M; Lavelli V; Donegani MI; Ponzano M; Gaudiano A; Stazza ML; Licari M; Cavallini L; Laghi V; Cindolo L; Maggi M; Sciarra A; Mammucci P; Sambuceti G; Costa RP; Spanu A; Rubini G; Monari F; De Vincentis G; Fornarini G
Eur J Nucl Med Mol Imaging; 2022 Feb; 49(3):1063-1074. PubMed ID: 34486070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
